Precision BioPartners

When Gabriele Ricci became our Chief Data and Technology Officer, he eliminated the term "IT," emphasizing its role as a business function. Under his leadership, we created a new data, digital and technology function, reimagining how we operate to drive our digital transformation. Read the full feature in Fortune: https://lnkd.in/ejVGv4_f #DigitalTransformation?#Innovation #AI

‘Poseida Therapeutics, Inc., a clinical-stage allogeneic #celltherapy and #geneticmedicine company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Roche Holdings, Inc. ("Roche") at a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones. This corresponds to a total equity value of approximately $1.5 billion on a fully diluted basis. The merger agreement has been unanimously approved by Poseida's Board of Directors.’ ‘The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will include CAR-T programs for solid tumors and autoimmune diseases, along with Poseida's #geneticengineering platform and related #preclinical medicines. Poseida has pioneered a proprietary technology platform that includes a full set of non-viral capabilities to design, develop and manufacture allogeneic, T stem cell memory cells (TSCM)-rich CAR-T therapies. TSCM cells are considered ideal for CAR-T therapy because they are long-lived, multi-potent and self-replicating, with the potential for an improved safety and efficacy profile. This may offer benefits compared to other approaches, which either use a different cell type or drive #tcell differentiation (and therefore less stemness) as part of the process to manufacture the #CART cells. "Poseida has demonstrated the unique ability of its proprietary non-viral technology platform to create allogeneic, TSCM-rich #CAR-T therapies with the potential to improve clinical outcomes and expand access to this important class of medicines. Most recently, this was highlighted by the compelling interim clinical data for P-BCMA-ALLO1 in patients with multiple myeloma," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida Therapeutics. "We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues together across our pipeline and future programs. Roche's global capabilities in late-stage development and commercialization will enable patients worldwide to benefit from the transformative potential of allo CAR-T." https://lnkd.in/eprENiPN

We attended MIT's 2024 NeuroTech Symposium on Wednesday. It was a pleasure to be in the company of many pioneers whose curiosity, rigor, and innovation are changing the face of neurobiological research. Thank you to our gracious hosts, presenters, and scientists who are driving such meaningful work. If we didn't have an opportunity to connect, I look forward to introductions in the coming weeks. Please feel free to message me here or my email is [email protected]. Massachusetts Institute of Technology McGovern Institute for Brain Research The Picower Institute for Learning and Memory MIT Department of Biological Engineering MIT Brain and Cognitive Sciences Ed Boyden, Alan Jasanoff,Vincent Pieribone, Fritjof Helmchen, Shannon Stott, Jerzy Szablowski, Laura Lewis, Angelique Christine Paulk, Claudia Cea, Ying Jiang, Sarah Spitz, Zeguan Wang #neuroscience #neurologicalresearch #bioengineering #research #science #innovation #biologicalengineering #neurotechnology #stem #biotech #techbio #biotechnology #mit #neurotech2024 #meaningfulresearch #neurotech #scienceandtechnology

Biomedical AI for Precision Health INTERNSHIP at Microsoft Research! ? Design & implement state-of-the-art systems in consideration of medical factors and responsible #AI principles. ? Analyze multimodal real-world data (#RWD) sources, such as #EHR, #medicalimaging, and multi #omics to explore opportunities for modeling. ? Propose novel approaches for unsolved research problems. Apply through the link: https://lnkd.in/gArc37qD #intern #internship #internships #techbio #ai #biomedical #biomedicalresearch #research #stem #science #tech #engineering #mathematics #phd #computerscience #scienceandtechnology

Which data types should you try to be familiar with for current computational biology job postings? Just went to an AACR Special Conference, and pretty much every study presented used bulk and single-cell RNA-seq. These two data types are very, very common. (A handful of studies additionally used spatial transcriptomics and multiplex IHC.) This emphasis on bulk and single-cell RNA-seq data matches what I’m seeing in many current compbio job postings and is a pretty good indicator for what you want to demonstrate experience with to be competitive for these jobs. Everything I talked about above has an omics bias. I should note that a whole other sector of compbio jobs deal with in silico generation or vadiation of small molecules, RNAs, and antibodies/proteins as therapeutics. #compbio #computationalbiology #bioinformatics

?? New Advancements in CRISPR-Cas9! ?? Exciting news in the world of genome editing! AstraZeneca scientists have just published a paper describing the rational engineering of PsCas9 to improve editing efficiency. Key Highlights: ? Boosting Editing Efficiency: Non-optimized PsCas9 and sgRNA delivered via lipid nanoparticles (LNPs) initially showed low editing efficiency compared to adenoviral vector delivery.? ? Crystal-Clear Insights: Using Cryo-EM, they captured high-resolution structures of PsCas9 in complex with its sgRNA, unlocking detailed insights for enhancement.? ? Smart Redesign: Through rational design, they optimized both the sgRNA and PsCas9, creating a more efficient genome editor.? ? Impressive Results: The optimized PsCas9 and sgRNA delivered by LNPs achieved an average of 60% editing efficiency, significantly outperforming the ~20% efficiency of the gold standard SpCas9! This groundbreaking work demonstrates how optimizing genome editors can lead to highly efficient genome editing without relying on adenoviral vectors. A great leap forward for genome editing therapies! Dive into the full study here: https://lnkd.in/gdhMCxJf #RNA #CRISPR #GenomeEditing #DrugDevelopment

Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates! #biotech #biotechresearch #researchanddevelopment #innovation #drugdevelopment

Novartis acquires Kate Therapeutics to strengthen strategic priorities in #genetherapy and #neuroscience. Transaction projected to be worth 1.1 billion in total, comprising an upfront payment and potential additional milestone payments. Novartis secures enabling technology platforms and therapeutic candidates for DMD, FSHD and DM1, currently in preclinical development. #Pharma #Biotech #BiomedicalResearch #CellAndGeneTherapy #Genetics #NeurodegenerativeDisease https://lnkd.in/eAz_97mT

?????????? ?????????? ???? ?????????????????????????? ??????????????????: Recursion ?????? ???????????????????? ???????????????? ???????? Exscientia. This is a momentous day for pioneering new ways to deliver better solutions for patients. ?? ????????: ?????? ???? ?????? ?????????? - ?????? 10/10/10 ?????????????????? ?????????? ?? Pipeline Advancement: Rapidly advancing 10 clinical and preclinical programs across oncology, rare diseases, and more ?? First-in-Class Discovery: Progressing 10 advanced discovery programs, primarily first-in-class assets ?? Strategic Partnerships: Driving 10+ partnered programs with leading pharmaco in oncology, immunology, and neuroscience: ?? $450M in upfront and milestones realized to date ?? Sanofi: Achieved milestones for 3 programs ?? Bayer: 2 oncology programs advancing to series nomination ??Roche/Genentech: Delivered the world’s first phenomap realizing $30M ?? ??????: ?????? ???????? ???? ?????????????? ?? ?????????????????? ?????? ??????????????????????: ??To manage complexity and maximize impact, we are doubling down on areas where we have the right to win while deprioritizing 2 programs. Examples of focus areas: ??Oncology: Programs such as CDK7, RBM39, and others ??Rare Diseases: Programs such as FAP, ENPP1 ??Other: Recurrent C. diff. ???????? ???????????????? ????????????????????: ??REC-617 Ph 1 monotherapy safety, PK/PD data for solid tumors by year-end ??REC-4881 Ph 2 data for FAP in H1 2025 ??Launch of clinical trials for REC-4539 (LSD1i, SCLC), REC-3565 (MALT1i, B-cell malignancies) in 2025. ?????????????????? ?????????? ?????? ?????????????? ???? ????-?????????????? ?????????????????? & ??????????????????????: ??Focusing on solving major challenges, including: ??Strengthening multi-omics connections to link biology to disease ??Leveraging active learning to advance lead optimization ??Using ML to accelerate patient recruitment ???????? ?????????? "????????????????????????" ????????: ??Both teams bring the same passion, rigor, and collaborative “multilingual” approach of combining tech/AI + science ??This partnership embodies our “secret sauce”: doing things differently with humility required to make a medicine ?????? ???????? ?????????? The path forward will be challenging, with ups and downs, but the stakes are too high not to try. We need to reimagine success rates and costs—and above all, remember the patients who are waiting for us to deliver. Let’s get to work. https://bit.ly/48XwgvU

A breath of fresh air! We had a great time at Boston Pitchfest last week. With 70+ startups and a diverse group of investors, it was refreshing to be around so many intrinsically motivated founders innovating at the intersection of science and technology. If we didn't chat and you'd like to connect, please email [email protected]. Thank you to our hosts Buzzed for Biotech, Leader Bank, and Portal Innovations, LLC - Southline Labs. Biotechnology Innovation Organization Precision BioPartners dovetail biopartners Pliancy Collaborative Drug Discovery - CDD Vault Ontologic Hamilton, Brook, Smith & Reynolds, P.C. #biotech #biotechnology #biotechnologie #scienceandtechnology #startups #techbio #therapeutics #diagnostics #lifesciences #science #innovation #researchanddevelopment #stem #ai #ml #meaningfulscience #meaningfultech #technology #venturecapital #biopharma #pharma #pharmaceuticals #founders #JPM2025